Therapeutic index 'low': AMD treatment feasible, but Santen pulls out

Salt Lake City-IOMED Inc. and Santen Pharmaceuticals Co. said they have ended a joint development agreement intended to launch a noninvasive ophthalmic drug delivery system to provide an anti-angiogenic drug to the retina and choroid in therapeutic quantities.